[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-nerve\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-nerve":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100635258","bupivacaine-lidocaine-vs-bupivacaine-for-ultrasound-guided-popliteal-sciatic-nerve-block-100635258",false,"NCT07550348","Bupivacaine-Lidocaine vs Bupivacaine for Ultrasound-Guided Popliteal Sciatic Nerve Block","Bupivacaine-Lidocaine Combination Versus Bupivacaine Alone for Ultrasound-Guided Popliteal Sciatic Nerve Block in Elective Lower Extremity Surgery: A Prospective Randomized Double-Blind Trial","PSSNB-BL","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III\n* Scheduled for elective distal lower extremity surgery (below-knee)\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Morbid obesity (BMI ≥35 kg\u002Fm²)\n* Known allergy or hypersensitivity to any local anesthetic agent\n* Severe cardiac, hepatic, or renal disease\n* Pre-existing neurological deficits or peripheral neuropathy\n* Use of anticoagulant therapy\n* History of prior surgery or significant scar tissue in the popliteal fossa\n* Pregnancy\n* Chronic opioid use at home","ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective, randomized, double-blind clinical trial aims to compare the efficacy of two local anesthetic regimens for ultrasound-guided popliteal sciatic nerve block in adult patients undergoing elective distal lower extremity surgery.\n\nEligible participants (ages 18-65, ASA physical status I-III, BMI 18-35 kg\u002Fm²) will be randomized into two equal groups of 30. Patients in Group BL will receive a combination of 10 mL 2% lidocaine and 10 mL 0.5% bupivacaine, while patients in Group B will receive 20 mL 0.5% bupivacaine alone, administered via ultrasound-guided popliteal sciatic nerve block prior to surgery.\n\nThe primary outcome is the onset time of sensory and motor blockade. Secondary outcomes include block success rate, duration of sensory and motor block, postoperative opioid consumption, pain scores assessed by the Numeric Rating Scale (NRS) at 2, 4, 8, 12, and 24 hours postoperatively, Quality of Recovery-15 (QoR-15) score, and incidence of rebound pain.\n\nThe study is conducted at Ataturk University Research Hospital, Department of Anesthesiology and Reanimation, Erzurum, Turkey.",[28,29,30,31],"Lower Extremity","Nerve Block","Pain, Postoperative","Pain, Nerve",[33,34,35,36,37,38,39,40,41,42],"Popliteal sciatic nerve block","Bupivacaine","Lidocaine","Local anesthetic","Ultrasound-guided nerve block","Regional anesthesia","Postoperative analgesia","Block onset time","Lower extremity surgery","QoR-15","RECRUITING","2026-05-08",{"date":46,"type":47},"2026-05-12","ACTUAL",{"date":49,"type":47},"2025-12-01",{"date":51,"type":22},"2027-03-01",{"name":53,"class":54},"Ataturk University","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":55},"100530364","phase-2-non-invasive-pulsed-radiofrequency-for-the-treatment-of-neuropathic-pain-100530364","NCT06185816","Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain","Inclusion Criteria:\n\n* -Adults aged 18 or older with clinically diagnosed chronic neuropathic pain after peripheral injury defined as persistent or recurrent neuropathic pain caused by a peripheral nerve lesion, history of a plausible nerve trauma, pain onset in temporal relation to the trauma, and pain distribution within the innervation territory of a peripheral nerve (or nerves). Negative and positive sensory symptoms or signs must be compatible with the innervation territory of the affected nerve. Can be posttraumatic, post-surgical, nerve compression, nerve ischemia with or without loss of motor function\n* Positive response (at least 50% pain relief) to diagnostic nerve block at the suspected site of CNP-PI.\n* Continued pain despite conservative therapy for a minimum of 12 weeks\n* Stable dosage of analgesic medications for at least 30 days, and willingness to refrain from trialing new analgesic medications for three weeks after randomization\n* Worst pain intensity of ≥5\u002F10 on the Numeric Rating Scale (NRS) of Pain (0-10) at the CNP-PI site at enrollment\n* English-speaking\n* Ability and willingness to complete online and phone assessments\n\nExclusion Criteria:\n\n* Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)\n* Cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome\n* Painful polyneuropathy (e.g., metabolic, autoimmune, familial, infectious disease, environmental toxins, treatment with neurotoxic drug)\n* Chronic central neuropathic pain (e.g., spinal cord injury, brain injury, multiple sclerosis)\n* Peripheral vascular disease\n* Diabetic neuropathy\n* Other active implantable devices (e.g., implantable cardioverter defibrillator, spinal cord stimulator, dorsal root ganglion stimulator, sacral nerve stimulator, deep brain stimulator, intrathecal pump)\n* Pregnancy, breastfeeding, or planning to conceive\n* Systemic infection or local infection at the anticipated NIPRF treatment sites\n* Interventional procedure and\u002For surgery to treat CNP-PI in the last 30 days (subjects should be enrolled 30 days after last procedure, for prior ablative treatment must be enrolled at least 3 months after last procedure)\n* Epilepsy\n* Metal implants within the target treatment area of the NIPRF.",{"count":63,"type":22},95,[65,66],"PHASE2","PHASE3","The purpose of this study is to examine non-invasive pulsed radiofrequency (NIPRF) and the effect it has on chronic neuropathic pain. Chronic neuropathic pain after peripheral nerve injury most often occurs in the context of post-traumatic or post-surgical pain. It is often treated with nerve blocks, prescription medication, physical therapy, neuromodulation, and surgery. The study team will be examining the efficacy of NIPRF and determining if it would be an appropriate treatment for chronic neuropathic pain after peripheral nerve injury.The Stimpod used in the present study is FDA approved and will be used for on label purposes.",[31],"2026-04-21",{"date":71,"type":47},"2026-04-24",{"date":73,"type":47},"2024-11-01",{"date":75,"type":22},"2029-01-01",{"name":77,"class":54},"Stanford University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100439984","surgical-treatments-for-postamputation-pain-100439984","NCT05009394","Surgical Treatments for Postamputation Pain","Inclusion Criteria:\n\n* The participant must have a major limb amputation.\n* The participant is ≥ 18 years old at the time of consent.\n* The participant must be in generally good health to undergo a surgical intervention, as per the clinical investigator's opinion.\n* Time since the last amputation must be over a year at the time of consent.\n* The participant must have an average residual limb pain score equal or greater than 4 on the Numerical Rating Scale (NRS, 0-10) after the baseline period.\n* If the participant has been prescribed pharmacological treatments for pain, there must be no variations in dosage (steady consumption) for at least 1 month before the screening visit.\n* If the participant has been prescribed non-pharmacological treatments for pain, such as spinal cord stimulation, transcutaneous electrical nerve stimulation, and mirror therapy, the treatment must have ended at least 1 month before the screening visit.\n* The participant must have a stable prosthetic fitting for at least a month before the screening visit.\n* The participant has a sufficient understanding of the language in which the assessments will be conducted, as per the clinical investigator's opinion.\n\nExclusion Criteria:\n\n* Neurological or other conditions that affect nerve regeneration for the nerve to be treated.\n* Active infection in the residual limb.\n* Prior RPNI or TMR surgery of the nerve to be treated (with painful neuroma) to address postamputation pain.\n* Mental disorders (e.g., schizophrenia, paranoia, psychosis, etc.), reluctance, or language difficulties that result in difficulty understanding the meaning of study participation.\n* Ongoing participation in a clinical study that the clinical investigator deems detrimental to participation in this study.",{"count":85,"type":22},110,[25],"This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP). The three surgical treatments are Targeted Muscles Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), and an active control (neuroma excision and muscle burying). Patients will be follow-up for 4 years.",[89,90,91,92,31],"Residual Limb Pain","Amputation Neuroma","Phantom Limb Pain","Pain, Neuropathic","2025-01-07",{"date":95,"type":47},"2025-01-09",{"date":97,"type":47},"2023-06-20",{"date":99,"type":22},"2029-06",{"name":101,"class":54},"Prometei Pain Rehabilitation Center",9]